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Identification of Chemically Sulfated/desulfated 
Glycosaminoglycans in Contaminated Heparins  
and Development of a Simple Assay for the Detection  
of Most Contaminants in Heparin
Jing Pan, Yi Qian, Xiaodong Zhou, Andrew Pazandak, sarah B. Frazier, Peter Weiser, hong Lu  
and Lijuan Zhang
1Equal Contribution first authors. Department of Pathology and Immunology, Washington University School of Medicine, 
St. Louis, MO 63110. Email: ljzhang@wustl.edu
Abstract: Contaminated heparin was linked to at least 149 deaths and hundreds of adverse reactions. Published report indicates that 
heparin contaminants were a natural impurity, dermatan sulfate, and a contaminant, oversulfated chondroitin sulfate (OSCS). OSCS 
was assumed to derive from animal cartilage. By analyzing 26 contaminated heparin lots from different sources, our data indicate that 
the heparin contaminants were chemically sulfated or chemically sulfated/desulfated glycosaminoglycans (GAGs) consisting of hepa-
ran sulfate, chondroitin sulfate, and dermatan sulfate based on monosaccharide quantification, CE, heparin lyase digestion, and liquid 
chromatography/mass spectrometry analysis. Since currently recommended heparin quality control assays had failed to detect certain 
heparin contaminants, a simple method that detects most contaminants in heparin was developed. This assay detects specific heparin 
structures that most contaminants cannot mimic and can be performed in any laboratory equipped with an UV spectrometer.
Keywords: heparin, contaminants, oversulfated chondroitin sulfate, glycosaminoglycan
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Introduction
Glycosaminoglycans (GAGs) are linear polysaccha-
rides comprised of repeating hexosamine-containing 
disaccharides made by all animal cells. Heparin is a 
GAG made mainly by mast cells. Heparin is widely 
used as an anticoagulant for treatment and prevention 
of thromboembolic disorders.1
Contaminated heparin was linked to at least 149 
deaths2 and hundreds of adverse reactions in the US 
and Germany in 2007 and 2008.3 The contaminants 
in heparin were reported as an impurity, specifically 
dermatan sulfate, and a contaminant, chemically 
oversulfated chondroitin sulfate (OSCS), presumed 
to derive from animal cartilage chondroitin sulfate 
based on NMR analysis.4
Heparin is prepared from crude heparin that is usu-
ally isolated from porcine intestine or bovine lung 
entrails. Crude heparin consists of ∼50% heparin and 
∼50% less sulfated GAGs, including heparan sulfate, 
dermatan sulfate, and chondroitin sulfate.5 The less 
sulfated GAGs are removed from crude heparin dur-
ing pharmaceutical grade heparin production into two 
heparin byproducts named GAG waste and tank bot-
tom.6 GAG waste has a NMR profile highly resembles 
heparin6 but it consists of less sulfated heparin/heparan 
sulfate and dermatan sulfate. The tank bottom consists 
of even less sulfated heparan sulfate, chondroitin sul-
fate, and dermatan sulfate.
The less sulfated GAG waste and tank bottom 
have low anticoagulation activities compared to the 
highly sulfated heparin. However, enriching 3-O-
sulfated heparin/heparan sulfate sequences by chemi-
cal sulfation/desulfation7 can greatly enhance the 
anticoagulation activities of the GAG waste enriched 
in heparin/heparan sulfate. In contrast, only fully 
chemical sulfation can turn each component of tank 
bottom, i.e. chondroitin sulfate,8 dermatan sulfate, 
and heparan sulfate, into better anticoagulants.9 Fur-
thermore, mixing heparin with OSCS could further 
enhance the anticoagulation activities of the mixture 
at therapeutic concentrations by an unknown molecu-
lar mechanism.10
Since the tank bottom can be a pure chondroitin 
sulfate if the crude heparin is isolated from bovine 
lung,11 the possibility exists that the OSCS observed in 
contaminated heparin might be derived from the tank 
bottom heparin byproduct rather than from animal 
cartilage chondroitin sulfate. Similarly, chemically 
sulfated/desulfated GAG wastes might be present in 
contaminated heparin if GAG waste was also used for 
adulteration.
To test the possibilities, we analyzed 26 heparin 
lots by monosaccharide quantification, CE, heparin 
lyase digestion, and liquid chromatography/mass 
spectrometry analysis. The heparin contaminants had 
faster, slower, or the same migration rate as heparin 
based on CE analysis. The heparin contaminants that 
had slowest migration rate indicated by CE analy-
sis was identified as chemically sulfated/desulfated 
heparin/heparan sulfate and chemically sulfated/
desulfated chondroitin/dermatan sulfate by liquid 
chromatography/mass spectrometry analysis, which 
suggests that chemically sulfated/desulfated GAG 
wastes are part of heparin contaminants.
Since currently recommended NMR, CE, and 
anion exchange HPLC-based heparin quality control 
assays are not able to identify all heparin contami-
nants in contaminated heparins, we developed a sim-
ple method that quantifies specific heparin structures, 
and that can detect most heparin contaminants. We 




Contaminated heparins used in this study were sup-
plied by the US FDA. The authentic heparin sample 
used in this study was purchased from Sigma. The 
96 well UV transparent plates used for heparin lyase 
I digestion were purchased from BD Bioscience. All 
heparin lyases were either purchased from Sigma or 
expressed in E. Coli and purified in our laboratory 
according to the published method.
Uronic acid analysis
Uronic acids were measured using the simplified 
carbazole assay.12 In brief, a PCR instrument was 
set at 100 °C for the hydrolysis and carbazole reac-
tions. The reagents used in the carbazole assay were 
0.025M sodium tetraborate⋅10 H2O in sulfuric acid 
(H2SO4+Borex) and 0.125% carbazole in absolute 
ethanol (W/V). Two hundred µl of the H2SO4+Borex 
solution to 40 µl of GAG solution or water (blank 
control). The tubes were capped and vortexed briefly. 
The tubes were then put into a PCR instrument with 
the lid securely locked. The PCR instrument was 
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programmed to run for 15 min at 100 °C and then 
cool down to 4 °C. To each tube, 8 µl of carbazole 
solution was added followed by a brief vortex. The 
tubes were returned to the PCR instrument for the 
carbazole reaction, which was run at 15 min at 100 °C 
and then cooled to 4 °C. The samples were vortexed 
and 200 µl of each sample was transferred to a 96 
well plate. The absorbance at 530 nm was measured 
by a Spectra MAX M2 plate-reading spectrophotom-
eter (Molecular Devices, Sunnyvale, CA). GlcA was 
used as an external standard, and the standard curve 
was derived by plotting absorbance against the con-
centration of GlcA or standard GAG.
Glucosamine- and galactosamine-
quantification of heparin samples
Glucosamine- and galactosamine-containing GAGs 
in heparin was analyzed by reversed-phase HPLC 
separation using the fluorescent isoindole derivatiza-
tion method.13 Two × 1 µl of 2 mg/ml stock solutions 
of heparin samples were subjected to acid hydrolysis, 
sodium borohydride reduction, precolumn derivatiza-
tion with o-phthaldialdehyde (OPA) and 3-mercapto-
propionic acid (3MPA), and reversed phase HPLC 
separation with fluorescence detection of the isoin-
dole derivatives. GAG aliquots containing 360 pmol 
of norleucine as an internal standard were dried in 
pyrolized glass vials (Agilent, Palo Alto, CA, part 
5181–8872) before hydrolysis with HCl vapor in N2 
gas at 100 °C for 3 hours. The samples were rehydrated 
in 45 µl of 0.56% NaBH4 to reduce the glucosamine 
and galactosamine liberated by acid hydrolysis into 
glucosaminitol and galactosaminitol, respectively. 
After an overnight incubation at room temperature, 
the reaction was terminated by adding 5 µl of 2N 
acetic acid to each vial. The sample was dried by cen-
trifugation under vacuum and dissolved in 5 µl water 
for precolumn derivatization with 35 µl of 7.5 mM 
OPA, 375 mM 3MPA, in 0.4N borate adjusted to pH 
9.3 with NaOH. Half of this reaction mixture was 
injected onto a 4.6 × 250 mm C-12 column, a Syn-
ergi 4 µ MAX-RP 80 Å (Phenomenex, Torrance, CA, 
part 00G-4337-E0), and heated to 35 °C. The column 
was equilibrated with Buffer A, consisting of 0.05 M 
(monobasic and dibasic) sodium phosphate, pH 7.2 in 
25% methanol, at a flow rate of 0.8 ml/min. Buffer B 
consisted of methanol, water, and tetrahydrofuran at 
70:30:3 volume ratios. After injection, Buffer B was 
increased from 0 to 8% by a linear gradient between 
0 and 3 min, was maintained at 8% between 3 and 
18 min, at 55% between 18 and 30.5 min, at 100% 
between 30.5 and 32.5 min, and at 0% between 32.5 
and 35 min. A 5 min post-run interval at 0% B pre-
ceded the initiation of the next precolumn derivatiza-
tion injection sequence. The fluorescent derivatives of 
glucosaminitol, galactosaminitol, and the amino acids 
contained in the GAG lots were excited at 337 nm 
and detected at 454 nm. All analyses were repeated 
twice. A more detailed description including statisti-
cal analysis of the assay can be found in the original 
publication.13
Low ph nitrous acid treatment
An established low pH nitrous treatment procedure 
was used to degrade heparin and contaminated hepa-
rin samples.14 In brief, samples were treated with 
HNO2 at pH 1.5 for 10 minutes on ice, followed 
by either NaBH4 or NaBD4 reduction. The residual 
NaBH4 and NaBD4 were destroyed by acetic acid. 
The samples were lyophilized and dried for liquid 
chromatography/mass spectrometry.
enzymatic digestion of heparin/heparan 
sulfate and chondroitin sulfate/dermatan 
sulfate
One hundred µg of heparin or contaminated heparin 
(2 mg/ml in water) were digested with ∼1 mU heparin 
lyases I, II, and III, 1 mU heparin lyase I, or 1 mU 
heparin lyase I in 200 µl of buffer containing 50 mM 
ammonium acetate and 0.125 mM calcium acetate 
pH 7. Chondroitin/dermatan sulfate was digested by 
chondroitinase ABC (Seikagaku, Tokyo) in 200 µl 
of buffer containing 50 mM Tris and 50 mM sodium 
acetate, pH 8.0. The extent of digestion was monitored 
every 2 min for 120 min at 37 °C by reading absor-
bance at 232 nm in a 96 well plate reader (Molecular 
dynamics).
Aniline tagging
Ten µl aniline or D5-aniline was added to heparin lyase 
digested contaminated heparin samples followed by 
addition 7 µl 1 M NaBH4 in DMSO and 3 µl glacial 
acetic acid. The labeling reaction was carried out at 
65 °C for 2 h. The samples were dried by lyophiliza-
tion and dissolved in 10 µl of water.
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Liquid chromatography/mass 
spectrometry
The methods used in the studies were published 
elsewhere.15–17 Heparin lyase digested samples were 
labeled with H-aniline or D5-aniline by reductive 
amination. In contrast, low pH nitrous acid degraded 
samples were labeled with NaBH4 or NaBD4. Tag-
ging samples with different stable isotopes allow 
simultaneous comparison of two samples, which 
eliminates variation during and between analyses 
associated with liquid chromatography/mass spec-
trometry methodology. Separations were performed 
on a 0.3 × 250 mm C18 column (Zorbax 300SB, 
5 µm, Agilent) using an Agilent 1100 series capillary 
HPLC workstation (Agilent, Palo Alto, CA) with 
Chemstation software for data acquisition, analysis, 
and management. The capillary HPLC was directly 
coupled to the mass spectrometer. Mass spectra were 
acquired on a Mariner BioSpectrometry Workstation 
ESI time-of-flight mass spectrometer (PerSeptive 
Biosystems; Framingham, MA) in the negative-ion 
mode. Total ion current chromatograms and mass 
spectra were processed with Data Explorer software 
version 3.0.
ce
CE was conducted on a Hewlett Packard 3D-CE 
instrument equipped with a diode array detector set 
at a wavelength of 200 nM (band width 10 nM) as 
described previously.18 Separations were performed 
in a bare fused silica capillary, internal diameter 
50 mM, 64.5 cm-total length, 56 cm-effective length 
with a column temperature of 25 °C. The polar-
ity was negative with a voltage of 30 kV. Samples 
were dissolved in Milli-Q water at a concentration of 
approximately 10 mg/ml and filtered through 0.2 mM 
cellulose acetate membrane filters (Micro-Spin filter 
tubes, Alltech Associates, Deerfield, IL, USA). The 
sample solutions were injected using hydrodynamic 
pressure at 50 mbar for 10 s. The electrolyte solution 
was 36 mM phosphate buffer (pH 3.5) filtered with a 
0.2 mM cellulose acetate syringe filter (Grace, Deer-
field, IL, USA). The capillary column was precondi-
tioned at the beginning of each day by flushing with 
1 M NaOH, 0.1 M NaOH, and water, each for 2 min, 
and prior to running each sample by flushing with 
water for 2 min and electrolyte solution for 2 min.
Results
Detect heparin contaminants  
by monosaccharide analysis
A simple way to distinguish GAG contaminants 
from other possible contaminants is to determine 
the amounts of glucosamine/galactosamine relative 
to uronic acids. Heparin/heparan sulfate consists of 
repeating glucosamine- and uronic acid-containing 
disaccharides whereas chondroitin/dermatan sul-
fate consists of repeating galactosamine- and uronic 
acid-containing disaccharides. Analysis of 26 lots of 
contaminated heparin from different sources showed 
similar amounts of uronic acid per gram dry weight 
compared to authentic heparin by a carbazole assay,12 
indicating that heparin was most likely contaminated 
with GAGs. By using a glucosamine and galactos-
amine quantification assay,12,13 we found variable 
amounts of galactosamine-containing contaminants in 
the 26 heparin lots (from 2–37%, Table 1) compared 
to 0.23% in the 26 authentic heparin lots. Although 
the glucosamine/galactosamine quantification assay 
quantifies the level of chondroitin/dermatan sulfate 
contamination, the assay could not exclude the pos-
sibility that heparin was also contaminated with hepa-
ran sulfate and/or oversulfated heparan sulfate. This 
assay also could not distinguish low-sulfated from 
over-sulfated chondroitin/dermatan sulfate.
Detect heparin contaminants  
by ce analysis
CE separates GAGs mainly by negative charge 
contributed by the uronic acids and sulfate groups. 
Thus, less sulfated GAGs migrate slower than hepa-
rin, whereas oversulfated GAGs migrate faster than 
heparin. Since heparin is the most sulfated naturally 
occurring GAG, any contaminant that migrates faster 
than or co-migrates with heparin is not natural, but 
rather represents one or more chemically sulfated 
contaminant(s). As shown in Figure 1A, authentic 
heparin eluted at 5.6 minutes. Six of the contami-
nated lots (lots LSCH1-6) contained a contaminant 
that eluted later at 6.5 minutes (Fig. 1B), which indi-
cates that the contaminant was less sulfated than 
heparin. Four samples (OSCH1-4) had a contaminant 
that eluted earlier than heparin at 5.2 minutes, indi-
cating it was more sulfated than heparin (Fig. 1C). 
Ten contaminated lots (OSLSCH1-10) had both more 
Heparin contaminant identification and quality control
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sulfated and less sulfated contaminants (OSC and 
LSC, respectively; Fig. 1D). Three lots (S1-3) con-
taining 3 to 5% galactosamine-containing GAGs had 
no contaminant detectable by CE (Fig. 1E). Another 
three lots from Germany (G1-3) had an additional 
low-sulfated contaminant peak eluting at 7.2 minutes 
(Fig. 1F). Thus, these heparin lots contained vari-
ous mixtures of low-sulfated and oversulfated GAG 
contaminants.
NMR had failed to detect G1, G2, G3, S1, S2, and 
S3 as contaminated heparin lots whereas currently 
recommended NMR, CE, and anion exchange HPLC 
analyses (data not shown) had failed to detect S1, S2, 
and S3 as contaminated heparin lots.
Identify heparin contaminants in G1, G2, 
and G3 by liquid chromatography/mass 
spectrometry analysis
The three contaminated heparin lots (G1, G2, and 
G3) were retrieved from Germany. These heparin lots 
had low amounts of galactosamine-containing GAGs 
by monosaccharide analysis (6%–8%, Table 1). The 
galactosamine-containing GAGs were susceptible to 
chondroitinase ABC digestion, but had an unusual com-
position compared to cartilage chondroitin sulfate and 
Figure 1. CE profiles of normal and contaminated heparin. ce was 
performed using the FDA recommended protocol (See material and 
methods). A, authentic heparin; B, heparin lot LSCH6 containing low-
sulfated contaminant (Lsc); c, heparin lot Osch4 containing an over-
sulfated contaminant (Osc); D, heparin lot OsLsch5 containing both 
oversulfated and low-sulfated contaminants; e, heparin lot s1, which we 
show contains oversulfated heparan sulfate; and F, heparin lot G1 con-
taining two low-sulfated contaminants. More detailed information about 
these samples is shown in Table 1 and in the text. ce reliably resolved 
abnormal peaks in most heparin lots (B-D, and F) but did not resolve 





















































Table 1. Monosaccharide composition of contaminated 
heparin lots. Twenty-six suspect heparin samples were 
acid hydrolyzed and analyzed chemically for galactosamine, 
glucosamine, and uronic acid content. The recovery of 
galactosamine and glucosamine relative to uronic acid 
was used to determine the relative amount of chondroitin/





Uronic acid  
(% of heparin)
Lsch1 2 ± 1.4 114 ± 6%
Lsch2 8.0 ± 1.0 114 ± 7%
LSCH3 9.6 ± 0.6 108 ± 7%
Lsch4 10.5 ± 2.1 124 ± 3%
Lsch5 13.8 ± 4.1 115 ± 3%
LSCH6 15.7 ± 0.6 122 ± 3%
Osch1 10.5 ± 1.5 100 ± 20%
Osch2 13.0 ± 1.0 109 ± 1%
OSCH3 13.9 ± 0.6 110 ± 10%
Osch4 23.6 ± 1.5 108 ± 0.7%
OsLsch1 9.6 ± 0.1 110 ± 13%
OsLsch2 11.0 ± 0.4 100 ± 16%
OSLSCH3 18.9 ± 0.8 110 ± 23%
OsLsch4 21.0 ± 1.2 110 ± 16%
OsLsch5 22.8 ± 1.4 120 ± 13%
OSLSCH6 23.3 ± 0.6 107 ± 3%
OsLsch7 23.7 ± 0.2 90 ± 10%
OsLsch8 29.1 ± 0.8 101 ± 3%
OsLsch9 29.3 ± 3.5 108 ± 0.7%
OsLsch10 37.1 ± 0.14 90 ± 10%
s1 2.5 ± 0.6 92 ± 5%
s2 3.5 ± 0.5 95 ± 3%
S3 3.8 ± 1.6 102 ± 3%
G1 8.7 ± 2.1 100 ± 2%
G2 7.3 110 ± 2%
G3 6.5 ± 0.6 107 ± 8%
The individual lots were analyzed for uronic acid, galactosamine and 
glucosamine after acid hydrolysis. The recovery of each hexosamine 
was used to determine the relative amount of chondroitin/dermatan 
sulfate and heparin/heparan sulfate, respectively.
Abbreviations: Lsch, low-sulfated contaminant containing heparin; 
Osch, oversulfated contaminant containing heparin; OsLsch, both 
oversulfated and low-sulfated contaminant containing heparin; s 
(suspected) lots passed both CE and NMR screen; G (Germany) lots 
passed screening by NMR but not by CE.
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porcine mucosal dermatan sulfate (Table 2). In these 
experiments, the products derived from chondroi-
tinase digestion, consisting mostly of disaccharides, 
were analyzed by NaBH4 reductive amination with 
isotope-tagged aniline and liquid chromatography/
mass spectrometry.15 This technique allows deter-
mination of the number of sulfate groups (and their 
position) on each disaccharide. As shown in Table 2, 
the chondroitin-like material in G1, G2, and G3 con-
sisted of non-sulfated disaccharides (55%–57% of 
the total), monosulfated disaccharides (18%–20%) 
and disulfated disaccharides (24%–27%). This pat-
tern differed significantly from shark cartilage chon-
droitin sulfate (97% monosulfated disaccharides) and 
porcine mucosal dermatan sulfate (18% non-sulfated 
disaccharides, 78% monosulfated disaccharides, and 
only 4% disulfated disaccharides).
As shown in Figure 1F, the heparin lots from 
Germany had substantial amounts of two low-sulfated 
contaminants that resolved from heparin by CE. The 
relatively low amounts of galactosamine-containing 
GAG (Table 1) suggested that these peaks contained 
mainly glucosamine-containing GAG. Liquid chro-
matography/mass spectrometry of products gener-
ated by combined heparin lyase I, II, and III digestion 
showed non-sulfated disaccharides (11%–23%) 
and trisulfated disaccharides (61%–73%) typical 
of heparin, and unusually large amounts of lyase-
resistant hexasulfated tetrasaccharides (4%–21%) 
compared to heparin (Table 2) CE analysis (Fig. 1) 
suggests that the contaminants In G1, G2, and G3 
are naturally occurring heparin by product. However, 
liquid chromatography/mass spectrometry analysis 
(Table 2) indicates that the heparin byproduct might 
have been chemically oversulfated then desulfated 
to enhance its anticoagulant activities.7 Indeed, G1, 
G2, and G3 had better anticoagulation activities com-
pared to un-adulterated heparin based on 4 indepen-
dent anticoagulation assays (unpublished results). 
Therefore, chemical oversulfation/desulfation might 
be the scheme employed to turn the GAG waste hep-
arin byproduct into a better anticoagulant and then 
added to heparin to create the contaminated heparin 
preparations.
Identify chemically modified 
heparin/heparan sulfate structures 
in contaminated heparins by liquid 
chromatography/mass spectrometry 
analysis
Since chemical sulfation/desulfation reactions are 
accompanied by GAG structure modifications through 
different side reactions,7 identifying structures that are 
Table 2. Sulfated di- and tetra-saccharides of three contaminated heparin lots from Germany. samples were digested 
with chondroitinase ABc or a mixture heparin lyases I, II and III and the products were derivatized by reductive amination 
with aniline. The tagged products were mixed with differentially isotope-tagged aniline derivatized standards and the 
mixture was analyzed by liquid chromatography/mass spectrometry. The recovery of the standards was used to determine 
the recovery of each disaccharide and tetrasaccharide from the sample.
Lyase digestion  
products
Samples (Galactosamine %) Standards






D-a 57% 56% 55% 18% 2%
D-a + 1s 19% 20% 18% 78% 97%
D-a + 2s 25% 24% 27% 4% 1%
Heparin/Heparan sulfate
D-A 23% 18% 11% 5%
D-H + 3S 73% 61% 70% 95%
D-H-U-H + 6S 4% 21% 19% 1%
The modified version of the disaccharide structure code was used to designate the core structure of the individual disaccharides and tetrasaccharides.21 
Although the position of the sulfate groups was determined by co-elution of standards, the isobaric species containing the indicated number of sulfate 
groups were summed together to simplify the presentation of the data. D, ∆4,5-unsaturated uronic acid; a, n-acetylgalactosamine; A, n-acetylglucosamine; 
h, glucosamine; U, GlcA or IdoA; s, sulfate.
Heparin contaminant identification and quality control
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not present in native heparan sulfate/heparin but pres-
ent in chemically modified heparin byproducts would 
provide direct evidence that heparin byproducts were 
modified to mimic heparin. Indeed, one abnormal acet-
ylated heparin/heparan sulfate structure that might be 
generated through an established N-O intramolecular 
acetyl migration reaction19 was reported.20
We decided to test if other chemically modified 
heparan sulfate/heparin structures are also present in 
contaminated heparin preparations. To this end, we 
systematically compared several heparin lots contain-
ing low sulfated contaminants (LSCH2 and LSCH4), 
oversulfated heparin contaminants (OSCH2), both 
low and oversulfated contaminants (OSLSCH4), 
or heparin-like contaminants that have passed both 
CE and NMR-based heparin quality control assays 
(S1, S2, and S3) by liquid chromatography/mass 
spectrometry analysis. Representative data are shown 
in Figure 2.
In Figure 2A, LSCH4 and OSCH2 were digested 
with a combination of heparin lyase I, II, and III. The 
digested LSCH4 was tagged with D-aniline and the 
digested OSCH2 with H-aniline followed by NaBH4 
reduction. Then an equal amount of the D-aniline 
tagged LSCH4 and H-aniline tagged OSCH2 were 
mixed and analyzed by liquid chromatography/mass 
spectrometry simultaneously. Seven di- and tetra-
saccharides (designated DA, DH+1S, DH+2S, DH+3S, 
Figure 2. Liquid chromatography/mass spectrometry analysis of reduced di- and tetrasaccharides. A) Heparin lyase digestion and liquid 
chromatography/mass spectrometry analysis. Lsch4 and Osch2 were digested by a mixture of heparin lyase I, II, and III. Osch2 was tagged with 
H-aniline and LSCH4 was tagged with D-aniline. Both tagged samples were reduced with NaBH4. An equal amount of samples was mixed and analyzed 
simultaneously by liquid chromatography/mass spectrometry. DA refers to a disaccharide containing an ∆4,5-unsaturated uronic acid (U) linked to n-
acetylglucosamine (A). UAUh refers to a tetrasaccharide composed of uronic acid (U, GlcA or IdoA)-n-acetylglucosamine (A)-uronic acid (U)-glucosamine 
(h). s refers to sulfate. B) Low pH nitrous acid degradation and liquid chromatography/mass spectrometry analysis. samples Lsch2, Lsch4, 
Osch2, and s1 were degraded with nitrous acid at ph 1.5 and the resulting saccharides of Lsch2 and Lsch4 were reduced with naBh4. Osch2 and 
S1 were treated similarly and reduced with NaBD4. Lsch4 was mixed with Osch2 whereas Lsch2 was mixed with s1. The mixtures were analyzed by 
liquid chromatography/mass spectrometry. UM refers to a disaccharide containing an unspecified uronic acid (U) linked to anhydromannitol (M). UAUM 
refers to a tetrasaccharide composed of uronic acid (U)-N-acetylglucosamine (A)-uronic acid (U)-anhydromannitol (M). S refers to sulfate.
Mariner Spec +213:372 (T +18.64:32.63)  ASC[BP = 189.0, 1324006]
Mariner Spec +273:308 (T +23.91:26.99)  ASC[BP = 189.0, 172074]
Mariner Spec +282:291 (T +24.70:25.49)  ASC[BP = 189.0, 62689]
Mariner Spec +252:280 (T +22.07:24.52)  ASC[BP = 189.0, 835581]
Mariner Spec +219:250 (T +19.17:21.89)  ASC[BP = 189.0, 241647]

































A. Heparin lyase digestion B. Nitrous acid digestion
Mariner Spec +346:396 (T +30.22:34.63)  ASC[BP = 189.0, 9858]
Mariner Spec +325:389 (T +28.39:34.01)  ASC[BP = 227.2, 8835]
Mariner Spec +341:407 (T +29.79:35.60)  ASC[BP = 189.0, 10841]
Mariner Spec +345:409 (T +30.14:35.77)  ASC[BP = 189.0, 10973]
Mariner Spec +258:304 (T +22.54:26.56)  ASC[BP = 629.2, 25427]
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DAUH+3S, DAUH+4S, DHUH+6S) along with two 
novel heparin/heparan sulfate structures (designated 
DAUA+1S+103 and DAUH+3S+103) in the LSCH4 
are shown in Figure 2A. (D stands for unsaturated 
uronic acid21 (∆UA), U stands for either glucuronic 
or iduronic acid, A stands for N-acetylglucosamine, 
H stands for glucosamine, S stands for sulfate, and 
103 stands for an unknown structure with a mass of 
103 Daltons). In contrast, only DA and DH+1S were 
observed in the OSCH2 (Fig. 2A), which indicates 
that oversulfated heparin byproducts inhibited hepa-
rin lyase I but not heparin lyase III digestion since 
a comparable amount of non-sulfated and N-sulfated 
disaccharides was produced in the OSCH2.
To determine if the novel DAUA+1S+103 and 
DAUH+3S+103 structures were artifacts associated 
with heparin lyase digestion/aniline labeling/NaBH4 
reduction of LSCH4, contaminated heparin samples 
LSCH2, LSCH4, OSCH2, LSOSCH4, S1, S2, and S3 
were treated with nitrous acid at pH 1.5. Cleavage 
in this way removes N-sulfate groups and generates 
2,5-anhydromannose at the reducing end.22 The 
identity of the nitrous acid generated di-, tetra-, and 
other saccharides was assessed by reducing the anhy-
dromannose residues to 2,5-anhydromannitol with 
sodium borohydride (NaBH4) or sodium borodeuteride 
(NaBD4), respectively. Then an equal amount of the 
H-NaBH4 tagged LSCH2 or LSCH4 and D-NaBD4 
tagged OSCH2 or S1 were mixed and analyzed by 
liquid chromatography/mass spectrometry simultane-
ously (Fig. 2B). Both OSCH2 and S1 showed enrich-
ment in multiply sulfated disaccharides (UM+2S) 
and tetrasaccharides (UAUM+1 to 3 S) compared to 
LSCH2 and LSCH4, suggesting that heparin/heparan 
sulfate in OSLSCH4 and S1 are more sulfated than 
that in LSCH2 and LSCH4, which was consis-
tent with the CE analysis result. Most importantly, 
UAUM+1S+103 and UAUM+2S+103 for H-NaBH4 
tagged LSCH2 and LSCH4 and UAUM+1S+104 and 
UAUM+2S+104 for D-NaBD4 tagged OSLSCH4 
and S1 were observed (Fig. 2B). We found that the 
unknown structures generated by H-NaBH4 tag-
ging (103) or D-NaBD4 tagging (104) after low pH 
nitrous acid digestion was a common feature of all 
the contaminated heparins tested (LSCH2, OSCH4, 
LSOSCH4, S1, S2, and S3). Therefore, indepen-
dent heparin lyase and nitrous acid treatments fol-
lowed by NaBH4 or NaBD4 reduction generated the 
same unknown heparin/heparan sulfate structures. 
These results indicate that the DAUA+1S+103 and 
DAUH+3S+103 structures (ion current intensities are 
shown in Table 3) were not artifacts of the assay sys-
tems but represented chemically modified heparin/
heparan sulfate because such structures were not 
detected in un-adulterated heparin or in other natu-
rally occurring heparan sulfate by using the same 
liquid chromatography/mass spectrometry analysis 
approach.15
establish a simple heparin  
quality control assay
Since certain contaminants cannot be detected by CE 
and/or NMR, and liquid chromatography/mass spec-
trometry analysis is an expensive and time consuming 
process for routine heparin quality control, we sought 
a technique to assess the purity of heparin based on 
its unique chemical structures recognized by heparin 
lyases that none of the contaminants can mimic. The 
liquid chromatography/mass spectrometry analysis 
indicates that oversulfated heparin contaminants spe-
cifically inhibited heparin lyase I but not heparin lyase 
III activities (Fig. 2A). Heparin lyase I specifically 
digests N-sulfated regions in heparin and heparan 
sulfate. The N-sulfated regions are more abundant in 
heparin than in heparan sulfate. Such properties make 
heparin lyase I digestion more specific for heparin 
detection compared to the combined heparin lyase 
I, II, and III digestions that detect both heparin and 
heparan sulfate equally well.
This assay monitors and quantifies the extent of 
heparin lyase I digestion by measuring the UV absorp-
tion at 232 nm of the unsaturated uronic acids gener-
ated during heparin lyase I digestion. The presence of 
contaminants (indigestible oversulfated GAGs, chon-
droitin sulfate, dermatan sulfate, non-sulfated regions 
of heparan sulfate, salts, and other macromolecules) 
reduces the expected absorbance.
To demonstrate the utility of this approach, the six 
heparin lots described in Figure 1 were digested by 
heparin lyase I in triplicate and the extent of diges-
tion was assessed (Fig. 3A). Lower UV absorbance 
was observed in the heparin lots containing low-
sulfated contaminants (LSCH6 ∆OD 0.358 ± 0.025) 
compared to authentic heparin (∆OD 0.470 ± 0.022). 
Heparin lots containing oversulfated contaminants 
(OSCH4 ∆OD 0.041 ± 0.001) or both oversulfated and 
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low-sulfated contaminants (OSLSCH5 ∆OD 0.049 ± 
0.003) were barely digestible. Contaminated heparin 
lots S1, S2, and S3, which have passed both FDA 
recommended CE and NMR screening, were only 
partially digestible by the enzyme (S1 ∆OD 0.085 ± 
0.010). Based on this data, we suggest that heparin 
lots that deviate by 5% from the expected absorbance 
values of authentic heparin should be tested further 
for possible contamination.
We also devised a second method based on the abil-
ity of oversulfated GAGs to inhibit heparin lyase I. In 
this assay, an aliquot of authentic heparin is mixed 
Figure 3. A) Detection of contaminated heparin by enzymatic assay. exactly 100 µg of heparin and the five contaminated heparin lots shown in 
Figure 1 were digested for 2 hr with 1 mU heparin lyase I in triplicate and the absorbance at 232 nm was recorded for 120 min. The maximum change 
in absorbance (OD) of 100 µg of digested samples is shown with standard deviation. B) Inhibition heparin digestion by chemically sulfated heparin 
byproduct and contaminated heparins. heparin (100 µg) alone or heparin plus chemically oversulfated heparin byproduct (Os-hB) or other contami-
nated heparins (OSCH4, OSLSCH5, and S1) in duplicates were digested with heparin lyase I and the absorbance at 232 nm was recorded every min for 
a total 120 min. each data point of 120 data points shown in each digestion curve was average values of two independent heparin lyase digestion reac-
tions. A) 100 µg heparin plus 0, 0.1, 1, 5, 10, or 50 µg of oversulfated heparin byproduct; B) 100 µg heparin plus 0, 0.1, 1, 5, 10, or 50 µg of contaminated 
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with different amounts of test sample and the extent 
of digestion is determined (Fig. 3B). This assay is 
extremely sensitive in detecting oversulfated con-
taminants. For example, 0.1% oversulfated heparin 
byproduct (1000 ppm) inhibited digestion of standard 
heparin by 50% (Fig. 3B). By using authentic hepa-
rin as a control, both of these methods are indepen-
dent of the specific activities or source of the heparin 
lyase I. Furthermore, these assays only require access 
to a UV spectrophotometer, as opposed to expensive 
NMR and CE equipment.
Discussion
The monosaccharide analysis of 26 contaminated 
heparin lots indicates that GAGs were the dominant 
contaminants in heparin (Table 1). However, the 
heparin contaminants varied from lots to lots in that 
the contaminants could have faster, slower, or the 
same migration rate as heparin based on CE analysis 
(Fig. 1). We provided direct evidence that chemically 
oversulfated and desulfated GAGs were present in 
contaminated heparin lots G1, G2, and G3 (Table 2). 
We further showed the presence of abnormal heparin/
heparan sulfate structures in different contaminated 
heparin lots (LSCH2, LSCH4, OSCH2, OSLSCH4, 
S1, S2, and S3 (Fig. 2 and Table 3). The abnormal 
structures, DAUA+1S+103 and DAUH+3S+103, had 
never been observed in heparin during the past.
Somehow, chemical desulfation reserved certain 
disulfated disaccharides in the modified chondroi-
tin/dermatan sulfate and the hexasulfated tetrasac-
charides in the modified heparin/heparin sulfate in 
G1, G2, and G3 samples (Table 2) by an unknown 
molecular mechanism. Overall, the non-sulfated 
disaccharides (Table 2) in the chemically modified 
chondroitin/dermatan sulfate and heparin/heparin 
sulfate dominated the overall charge density and gave 
the contaminants an under-sulfated phenotype based 
on the CE analysis (Fig. 1).
NMR analysis alone has failed to detect heparin 
contamination in six contaminated heparin lots (G1, 
G2, G3, S1, S2, and S3), whereas combined CE and 
NMR analysis have failed in 3 (S1, S2, and S3) out 
of 26 contaminated heparin lots in our current studies 
based on monosaccharide (Fig. 1 and Table 1), liq-
uid chromatography/mass spectrometry (Fig. 2 and 
Tables 2 and 3), and heparin lyase digestion studies 
(Figs. 3). Therefore, a reliable assay is needed for 
future heparin quality control.
Pair wise comparison of test heparin with un-
adulterated heparin by liquid chromatography/mass 
spectrometry after enzymatic or chemical degrada-
tion (Fig. 2 and Tables 2 and 3) represents a reliable 
assay for future heparin quality control. However, the 
sensitivity and simplicity of assaying heparin sam-
ples by heparin lyase I digestion represent a practical 
assay for determining the presence of contaminants 
in heparin. Moreover, it detects not only oversulfated 
GAGs but also other possible contaminants in hepa-
rin.23 Some contaminated heparin lots (e.g. G1, G2, 
and G3) produced higher UV absorbance compared 
to authentic heparin (Fig. 3). The presence of con-
taminants in these samples can be confirmed by CE 
(Fig. 1E) or anion exchange HPLC analysis. Thus, 
the enzymatic assays can be used independently or 
in conjunction with CE or DEAE-HPLC method to 
ensure that heparin is free of contaminants.
Heparin is one of the most widely used medica-
tions on a unit basis. Twelve million patients receive 
Table 3. Detection of oversulfated heparan sulfate 
in contaminated heparin by liquid chromatography/
mass spectrometry. A. Heparin lyase digestion and 
liquid chromatography/mass spectrometry analysis. 
Lsch4 and Osch2 were digested by a mixture of heparin 
lyase I, II, and III. Osch2 was tagged with h-aniline 
and LSCH4 was tagged with D-aniline. Both tagged 
samples were reduced with naBh. An equal amount of 
samples was mixed and analyzed simultaneously by liquid 
chromatography/mass spectrometry. The elution time and 
total ion current for the disaccharides, tetrasaccharides, 
and novel tetrasaccharides corresponding to the proposed 
structures were listed. The ratio of each structure in the 
two differentially tagged samples was determined.
Proposed 
structures




DA+0s 15.6 7559 13000 0.58
DH+1s 17.0 453 846 0.54
DH+3S 20.1 0 37000
DAUH+4s 23.3 0 1092
DHUH+6S 24.7 0 1675
DAUA+1s+103 25.8 0 4885
DAUH+3S+103 28.0 0 1003
DA refers to a disaccharide containing an ∆4,5-unsaturated uronic acid 
(U) linked to n-acetylglucosamine (A). UAUh refers to a tetrasaccharide 
composed of uronic acid (U, GlcA or IdoA)-n-acetylglucosamine 
(A)-uronic acid (U)-glucosamine (h). s refers to sulfate.
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heparin treatment annually in the US alone.24 Heparin 
interacts with 22% of plasma proteins25 and regulates/
balances many human physiological processes beyond 
its anticoagulation capability,26 which makes it an 
essential drug that people cannot do without. However, 
in a patient-specific manner, heparin can induce many 
contradicted side effects that have never been observed 
with any other drugs in modern medicine.
Despite heparin associated side effects, hepa-
rin remains a necessary life saving drug in modern 
medicine.1 Accumulated knowledge during the past 
70 years enables doctors to handle most of heparin-
associated side effects. Heparin should be kept clean 
for this reason alone.
Contaminated heparin has made the rare ana-
phylactoid reaction into an adverse event.3 More-
over, contaminated heparin is also associated with 
thrombocytopenia as long term side effects27,28 
where affected patients could lose arms, legs, toes, 
or lives due to thrombosis. Therefore, all forms of 
contaminated heparin should be detected and elimi-
nated from use. Keeping heparin clean will minimize 
heparin-associated public health risks considering 
hundreds of millions patients use heparin annually 
in the world.
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